Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sidhartha Tan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Toward Lung Ventilation Imaging Using Hyperpolarized Diethyl Ether Gas Contrast Agent

    by Nuwandi M. Ariyasingha, Raduanul H. Chowdhury, Anna Samoilenko, Oleg G. Salnikov, Nikita V. Chukanov, Larisa M. Kovtunova, Valerii I. Bukhtiyarov, Zhongjie Shi, Kehuan Luo, Sidhartha Tan, et al.

    Hyperpolarized 129Xe gas was FDA‐approved as an inhalable contrast agent for magnetic resonance imaging of a wide range of pulmonary diseases in December 2022. Despite the remarkable success in clinical research settings, the widespread clinical translation of HP 129Xe gas faces two critical challenges: the high cost of the relatively low‐throughput hyperpolarization equipment and the lack of 129Xe imaging capability on clinical MRI scanners, which have narrow‐bandwidth electronics designed only for proton (1H) imaging. To solve this translational grand challenge of gaseous hyperpolarized MRI contrast agents, here we demonstrate the utility of batch‐mode production of proton‐hyperpolarized diethyl ether gas via heterogeneous pairwise addition of parahydrogen to ethyl vinyl ether. An approximately 0.1‐liter bolus of hyperpolarized diethyl ether gas was produced in 1 second and injected in excised rabbit lungs. Lung ventilation imaging was performed using sub‐second 2D MRI with up to 2×2 mm2 in‐plane resolution using a clinical 0.35 T MRI scanner without any modifications. This feasibility demonstration paves the way for the use of inhalable diethyl ether as a gaseous contrast agent for pulmonary MRI applications using any clinical MRI scanner.


  • Tetrahydrobiopterin in Cell Function and Death Mechanisms

    by Jeannette Vasquez-Vivar, Zhongjie Shi, Sidhartha Tan

    Significance: Tetrahydrobiopterin (BH4) is most well known as a required cofactor for enzymes regulating cellular redox homeostasis, aromatic amino acid metabolism, and neurotransmitter synthesis. Less well known are the effects dependent on the cofactor's availability, factors governing its synthesis and recycling, redox implications of the cofactor itself, and protein–protein interactions that underlie cell death. This review provides an understanding of the recent advances implicating BH4 in the mechanisms of cell death and suggestions of possible therapeutic interventions. Recent Advances: The levels of BH4 often reflect the sum of synthetic and recycling enzyme activities. Enhanced expression of GTP cyclohydrolase, the rate-limiting enzyme in biosynthesis, increases BH4, leading to improved cell function and survival. Pharmacologically increasing BH4 levels has similar beneficial effects, leading to enhanced production of neurotransmitters and nitric oxide or reducing oxidant levels. The GTP cyclohydrolase-BH4 pairing has been implicated in a type of cell death, ferroptosis. At the cellular level, BH4 counteracts anticancer therapies directed to enhance ferroptosis via glutathione peroxidase 4 (GPX4) activity inhibition. Critical Issues: Because of the multitude of intertwined mechanisms, a clear relationship between BH4 and cell death is not well understood yet. The possibility that the cofactor directly influences cell viability has not been excluded in previous studies when modulating BH4-producing enzymes. Future Directions: The importance of cellular BH4 variations and BH4 biosynthetic enzymes to cell function and viability makes it essential to better characterize temporal changes, cofactor activity, and the influence on redox status, which in turn would help develop novel therapies. Antioxid. Redox Signal . 37, 171–183.


  • Faculty Opinions recommendation of Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.

    by Sidhartha Tan, Sanket Jani

    This is a groundbreaking research paper in which an individualized milasen, a splice-modulating antisense oligonucleotide, was created to treat a single patient suffering from Batten disease, which is a progressive neurodegenerating disease, and using a template from a previous drug, nusinersen, to treat spinal muscular atrophy. The authors worked on an aggressive timeline not only to create a drug for that individual patient, but they were able to test the drug on fibroblast cells derived from the patient, receive regulatory approval from the FDA and get the commercially manufactured drug within 14 months. The treatment has helped the patient to resolve or decrease many of her symptoms. It is a feat that has rarely been achieved before. In one sense, this process serves as a template for overcoming what seems like a herculean task in clinical drug development but in another sense, one wonders about a future where drug development is biased towards diseases affecting people with resources and money.

  • Open Access

    Tetrahydrobiopterin in antenatal brain hypoxia-ischemia-induced motor impairments and cerebral palsy

    by Jeannette Vasquez-Vivar, Zhongjie Shi, Kehuan Luo, Karthikeyan Thirugnanam, Sidhartha Tan


  • Effect of Mn Porphyrins and Antioxidants on MRI Predictors and Behavior in an Animal Model of Cerebral Palsy

    by Lei Yu, Alexander Drobyshevsky, Matthew Derrick, Kehuan Luo, Ines Batinic-Haberle, Sidhartha Tan